Skip to main content
Top
Published in: Ophthalmology and Therapy 5/2023

Open Access 09-08-2023 | Glaucoma | REVIEW

New Devices in Glaucoma

Authors: Lilian Chan, Marlene R. Moster, Amanda K. Bicket, Arsham Sheybani, Steven R. Sarkisian, Thomas W. Samuelson, Iqbal Ike K. Ahmed, Eydie Miller-Ellis, Oluwatosin U. Smith, Qi N. Cui

Published in: Ophthalmology and Therapy | Issue 5/2023

Login to get access

Abstract

Glaucoma remains a leading cause of blindness globally. Minimally invasive treatment techniques are rapidly expanding the availability of therapeutic options for glaucoma. These include devices aimed at enhancing outflow through the subconjunctival space, Schlemm’s canal, and suprachoroidal space, sustained-release drug delivery devices, and extraocular devices aiming to reduce glaucomatous progression through other novel means. In this review, we provide an overview of several novel devices either newly available or in development for the medical and surgical management of glaucoma. Further studies are required to determine the long-term efficacy of these devices and how they will integrate into the current landscape of glaucoma management.
Literature
1.
go back to reference Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90.PubMedCrossRef Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90.PubMedCrossRef
2.
go back to reference Chen XZ, et al. The outcomes of XEN gel stent implantation: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9: 804847.PubMedCrossRef Chen XZ, et al. The outcomes of XEN gel stent implantation: a systematic review and meta-analysis. Front Med (Lausanne). 2022;9: 804847.PubMedCrossRef
3.
go back to reference Sheybani A, et al. Gel Stent vs Trabeculectomy: The Randomized, Multicenter, Gold Standard Pathway Study (GPS) of effectiveness and safety at 12 months: gel stent vs trabeculectomy: a prospective randomized study. Am J Ophthalmol. 2023;252:306–25.PubMedCrossRef Sheybani A, et al. Gel Stent vs Trabeculectomy: The Randomized, Multicenter, Gold Standard Pathway Study (GPS) of effectiveness and safety at 12 months: gel stent vs trabeculectomy: a prospective randomized study. Am J Ophthalmol. 2023;252:306–25.PubMedCrossRef
4.
go back to reference Midha N, et al. Efficacy of needling revision after XEN gel stent implantation: a prospective study. J Glaucoma. 2020;29(1):11–4.PubMedCrossRef Midha N, et al. Efficacy of needling revision after XEN gel stent implantation: a prospective study. J Glaucoma. 2020;29(1):11–4.PubMedCrossRef
5.
go back to reference Do A, et al. Comparison of clinical outcomes with open versus closed conjunctiva implantation of the XEN45 gel stent. Ophthalmol Glaucoma. 2021;4(4):343–9.PubMedCrossRef Do A, et al. Comparison of clinical outcomes with open versus closed conjunctiva implantation of the XEN45 gel stent. Ophthalmol Glaucoma. 2021;4(4):343–9.PubMedCrossRef
6.
go back to reference Tan NE, et al. Comparison of safety and efficacy between Ab interno and Ab externo approaches to XEN gel stent placement. Clin Ophthalmol. 2021;15:299–305.PubMedPubMedCentralCrossRef Tan NE, et al. Comparison of safety and efficacy between Ab interno and Ab externo approaches to XEN gel stent placement. Clin Ophthalmol. 2021;15:299–305.PubMedPubMedCentralCrossRef
9.
go back to reference Baker ND, et al. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12):1710–21.PubMedCrossRef Baker ND, et al. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12):1710–21.PubMedCrossRef
10.
go back to reference Saeed E, et al. The PreserFlo MicroShunt in the context of minimally invasive glaucoma surgery: a narrative review. Int J Environ Res Public Health. 2023;20(4):2904.PubMedPubMedCentralCrossRef Saeed E, et al. The PreserFlo MicroShunt in the context of minimally invasive glaucoma surgery: a narrative review. Int J Environ Res Public Health. 2023;20(4):2904.PubMedPubMedCentralCrossRef
11.
go back to reference Kao BW, et al. Biocompatibility and feasibility of VisiPlate, a novel ultrathin, multichannel glaucoma drainage device. J Mater Sci Mater Med. 2021;32(12):141.PubMedPubMedCentralCrossRef Kao BW, et al. Biocompatibility and feasibility of VisiPlate, a novel ultrathin, multichannel glaucoma drainage device. J Mater Sci Mater Med. 2021;32(12):141.PubMedPubMedCentralCrossRef
13.
go back to reference Xue L, Greisler HP. Biomaterials in the development and future of vascular grafts. J Vasc Surg. 2003;37(2):472–80.PubMedCrossRef Xue L, Greisler HP. Biomaterials in the development and future of vascular grafts. J Vasc Surg. 2003;37(2):472–80.PubMedCrossRef
14.
go back to reference Topart P, et al. Laparoscopic ventral hernia repair with the Goretex Dualmesh: long-term results and review of the literature. Hernia. 2005;9(4):348–52.PubMedCrossRef Topart P, et al. Laparoscopic ventral hernia repair with the Goretex Dualmesh: long-term results and review of the literature. Hernia. 2005;9(4):348–52.PubMedCrossRef
15.
go back to reference Bicket AK, et al. A novel bilayered expanded polytetrafluoroethylene glaucoma implant creates a permeable thin capsule independent of aqueous humor exposure. Bioeng Transl Med. 2021;6(1): e10179.PubMedCrossRef Bicket AK, et al. A novel bilayered expanded polytetrafluoroethylene glaucoma implant creates a permeable thin capsule independent of aqueous humor exposure. Bioeng Transl Med. 2021;6(1): e10179.PubMedCrossRef
17.
go back to reference Geffen N, et al. Minimally Invasive Micro Sclerostomy (MIMS) procedure: a novel glaucoma filtration procedure. J Glaucoma. 2022;31(3):191–200.PubMedCrossRef Geffen N, et al. Minimally Invasive Micro Sclerostomy (MIMS) procedure: a novel glaucoma filtration procedure. J Glaucoma. 2022;31(3):191–200.PubMedCrossRef
20.
go back to reference Samuelson TW, et al. Prospective, randomized, controlled pivotal trial of an Ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811–21.PubMedCrossRef Samuelson TW, et al. Prospective, randomized, controlled pivotal trial of an Ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811–21.PubMedCrossRef
21.
go back to reference Ahmed IIK, et al. Three-year findings of the HORIZON trial: a schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology. 2021;128(6):857–65.PubMedCrossRef Ahmed IIK, et al. Three-year findings of the HORIZON trial: a schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology. 2021;128(6):857–65.PubMedCrossRef
22.
go back to reference Iwasaki K, et al. Long-term outcomes of a kahook dual blade procedure combined with phacoemulsification in japanese patients with open-angle glaucoma. J Clin Med. 2022;11(5):1354.PubMedPubMedCentralCrossRef Iwasaki K, et al. Long-term outcomes of a kahook dual blade procedure combined with phacoemulsification in japanese patients with open-angle glaucoma. J Clin Med. 2022;11(5):1354.PubMedPubMedCentralCrossRef
23.
go back to reference Maeda M, Watanabe M, Ichikawa K. Evaluation of trabectome in open-angle glaucoma. J Glaucoma. 2013;22(3):205–8.PubMedCrossRef Maeda M, Watanabe M, Ichikawa K. Evaluation of trabectome in open-angle glaucoma. J Glaucoma. 2013;22(3):205–8.PubMedCrossRef
24.
go back to reference Grover DS, et al. Gonioscopy-assisted transluminal trabeculotomy, ab interno trabeculotomy: technique report and preliminary results. Ophthalmology. 2014;121(4):855–61.PubMedCrossRef Grover DS, et al. Gonioscopy-assisted transluminal trabeculotomy, ab interno trabeculotomy: technique report and preliminary results. Ophthalmology. 2014;121(4):855–61.PubMedCrossRef
25.
go back to reference Gallardo MJ, Supnet RA, Ahmed IIK. Viscodilation of Schlemm’s canal for the reduction of IOP via an ab-interno approach. Clin Ophthalmol. 2018;12:2149–55.PubMedPubMedCentralCrossRef Gallardo MJ, Supnet RA, Ahmed IIK. Viscodilation of Schlemm’s canal for the reduction of IOP via an ab-interno approach. Clin Ophthalmol. 2018;12:2149–55.PubMedPubMedCentralCrossRef
26.
27.
go back to reference Shah M. Micro-invasive glaucoma surgery—an interventional glaucoma revolution. Eye Vis (Lond). 2019;6:29.PubMedCrossRef Shah M. Micro-invasive glaucoma surgery—an interventional glaucoma revolution. Eye Vis (Lond). 2019;6:29.PubMedCrossRef
29.
go back to reference Salimi A, Watt H, Harasymowycz P. Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results. Eye Vis (Lond). 2021;8(1):43.PubMedCrossRef Salimi A, Watt H, Harasymowycz P. Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results. Eye Vis (Lond). 2021;8(1):43.PubMedCrossRef
30.
go back to reference Berlin MS, et al. Excimer laser photoablation in glaucoma filtering surgery. Am J Ophthalmol. 1987;103(5):713–4.PubMedCrossRef Berlin MS, et al. Excimer laser photoablation in glaucoma filtering surgery. Am J Ophthalmol. 1987;103(5):713–4.PubMedCrossRef
31.
go back to reference Huang S, et al. Histopathological study of trabeculum after excimer laser trabeculectomy ab interno. Yan Ke Xue Bao. 2001;17(1):11–5.PubMed Huang S, et al. Histopathological study of trabeculum after excimer laser trabeculectomy ab interno. Yan Ke Xue Bao. 2001;17(1):11–5.PubMed
32.
34.
35.
go back to reference Vold S, et al. Two-year COMPASS trial results: supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123(10):2103–12.PubMedCrossRef Vold S, et al. Two-year COMPASS trial results: supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123(10):2103–12.PubMedCrossRef
36.
go back to reference Lass JH, et al. Corneal endothelial cell loss and morphometric changes 5 years after phacoemulsification with or without CyPass micro-stent. Am J Ophthalmol. 2019;208:211–8.PubMedCrossRef Lass JH, et al. Corneal endothelial cell loss and morphometric changes 5 years after phacoemulsification with or without CyPass micro-stent. Am J Ophthalmol. 2019;208:211–8.PubMedCrossRef
37.
39.
go back to reference Myers JS, et al. Prospective Evaluation of Two iStent((R)) Trabecular Stents, One iStent Supra((R)) suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma: 4-year outcomes. Adv Ther. 2018;35(3):395–407.PubMedPubMedCentralCrossRef Myers JS, et al. Prospective Evaluation of Two iStent((R)) Trabecular Stents, One iStent Supra((R)) suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma: 4-year outcomes. Adv Ther. 2018;35(3):395–407.PubMedPubMedCentralCrossRef
41.
42.
go back to reference Denis P, et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial. Br J Ophthalmol. 2022;106(1):65–70.PubMedCrossRef Denis P, et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial. Br J Ophthalmol. 2022;106(1):65–70.PubMedCrossRef
43.
go back to reference iSTAR Medical Presents Positive Consistent Results for MINIject® across three international glaucoma trials. June 8, 2022: Wavre, Belgium. iSTAR Medical Presents Positive Consistent Results for MINIject® across three international glaucoma trials. June 8, 2022: Wavre, Belgium.
46.
go back to reference Medeiros FA, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–41.PubMedCrossRef Medeiros FA, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–41.PubMedCrossRef
47.
go back to reference Bacharach J, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017–33.PubMedPubMedCentralCrossRef Bacharach J, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017–33.PubMedPubMedCentralCrossRef
48.
go back to reference Brandt JD, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016;123(8):1685–94.PubMedCrossRef Brandt JD, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016;123(8):1685–94.PubMedCrossRef
50.
go back to reference Mansberger SL, et al. Interim analysis of low dose ENV515 Travoprost XR with 11 month duration followed by dose escalation and 28 day efficacy evaluation of high dose ENV515. Invest Ophthalmol Vis Sci. 2017;58(8):2110–2110. Mansberger SL, et al. Interim analysis of low dose ENV515 Travoprost XR with 11 month duration followed by dose escalation and 28 day efficacy evaluation of high dose ENV515. Invest Ophthalmol Vis Sci. 2017;58(8):2110–2110.
51.
go back to reference Vantipalli S, et al. Evaluation of the Safety and Efficacy of OTX-TP, an intracanalicular travoprost insert, for the treatment of patients with open-angle glaucoma or ocular hypertension: a phase 3 study. Invest Ophthalmol Vis Sci. 2020;61(7):3488–3488. Vantipalli S, et al. Evaluation of the Safety and Efficacy of OTX-TP, an intracanalicular travoprost insert, for the treatment of patients with open-angle glaucoma or ocular hypertension: a phase 3 study. Invest Ophthalmol Vis Sci. 2020;61(7):3488–3488.
52.
go back to reference Goldstein MH, et al. Evaluating safety, tolerability and efficacy of an intracameral hydrogel-based travoprost implant in subjects with glaucoma—phase 1 trial. Invest Ophthalmol Vis Sci. 2020;61(7):4266–4266. Goldstein MH, et al. Evaluating safety, tolerability and efficacy of an intracameral hydrogel-based travoprost implant in subjects with glaucoma—phase 1 trial. Invest Ophthalmol Vis Sci. 2020;61(7):4266–4266.
64.
go back to reference Glaukos submits new drug application to US FDA for iDose TR. 2023. Glaukos submits new drug application to US FDA for iDose TR. 2023.
65.
go back to reference Malihi M, Sit AJ. Effect of head and body position on intraocular pressure. Ophthalmology. 2012;119(5):987–91.PubMedCrossRef Malihi M, Sit AJ. Effect of head and body position on intraocular pressure. Ophthalmology. 2012;119(5):987–91.PubMedCrossRef
66.
67.
go back to reference Gulati V, et al. Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol. 2012;130(6):677–84.PubMedCrossRef Gulati V, et al. Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol. 2012;130(6):677–84.PubMedCrossRef
68.
go back to reference Swan RJ, et al. Evaluation of the IOP-lowering effect of a multi-pressure dial at different negative pressure settings. Transl Vis Sci Technol. 2020;9(12):19.PubMedPubMedCentralCrossRef Swan RJ, et al. Evaluation of the IOP-lowering effect of a multi-pressure dial at different negative pressure settings. Transl Vis Sci Technol. 2020;9(12):19.PubMedPubMedCentralCrossRef
70.
go back to reference Rahmatnejad K, et al. Non-invasive electrical stimulation for vision restoration: dream or reality? Expert Rev Ophthalmol. 2016;11(5):325–7.CrossRef Rahmatnejad K, et al. Non-invasive electrical stimulation for vision restoration: dream or reality? Expert Rev Ophthalmol. 2016;11(5):325–7.CrossRef
73.
go back to reference New Devices in Glaucoma. in American Academy of Ophthalmology. 2022. Chicago, IL. New Devices in Glaucoma. in American Academy of Ophthalmology. 2022. Chicago, IL.
Metadata
Title
New Devices in Glaucoma
Authors
Lilian Chan
Marlene R. Moster
Amanda K. Bicket
Arsham Sheybani
Steven R. Sarkisian
Thomas W. Samuelson
Iqbal Ike K. Ahmed
Eydie Miller-Ellis
Oluwatosin U. Smith
Qi N. Cui
Publication date
09-08-2023
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 5/2023
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-023-00780-3

Other articles of this Issue 5/2023

Ophthalmology and Therapy 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare